Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)
This website is intended exclusively for healthcare professionals and is provided for scientific exchange and educational purposes only. It is not intended for patients or the general public and does not constitute advertising, promotional activity or medical advice.
Content may include information about products, indications or uses that are not approved in all countries or regions, and may be subject to local regulatory requirements.
By continuing, you confirm that you are a healthcare professional and acknowledge the above.
You are now leaving the website
This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.
This link will take you to a third-party website outside of beonemedaffairs.com.
[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.
By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.
Do you want to leave beonemedaffairs.com
You are now leaving the the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed
